The Asia Pacific C-Reactive Protein Testing Market would witness market growth of 3.4% CAGR during the forecast period (2023-2030).
Diagnosing and treating cardiovascular diseases is one of the primary uses of CRP testing. Testing for CRP is frequently used to track individuals with a history of cardiovascular disease since elevated CRP levels are combined with an increased risk of heart attack and stroke. CRP testing is also utilized to diagnose and treat autoimmune diseases, lupus, and rheumatoid arthritis (RA), as well as infectious diseases like sepsis and pneumonia.
Compared to a usual CRP test, the hs-CRP test can detect inflammation and lower levels of CRP with more accuracy. For measuring CRP levels, it has a measurement range of 0.3 to 10 mg/L. The test is more reliable than typical CRP-based assays and has a narrower detection range than conventional methods.
This market is anticipated to be driven by technological advancements in the devices used to evaluate CRP levels in patients. Government initiatives are being implemented in developed and developing nations to promote the use of these testing in hospitals and other medical facilities. The market is expected to grow due to significant expenditure in developing new technology to increase CRP testing's consumption and accuracy. Unlike the conventional procedure, which takes 3 to 4 hours, the newly designed paper-based testing provides results in less than 5 minutes. The simplicity of use and increased adoption of CRP testing equipment are anticipated benefits of improved technology.
The National Library of Medicine reports that several studies have revealed significant variation, among which the overall incidence of osteoarthritis (OA) was 16.0. Osteoarthritis prevalence was 15.7% in East Asia and the Pacific and 16.4% in South Asia. In India, OA affected 62.35 million individuals in 2019. Over 26% of adults over 60 in Japan have symptomatic knee OA, while more than 60% of people over 60 have radiographic knee OA. Thus, the region's concerned organizations have stepped up their efforts to spread awareness of osteoarthritis. Since CRP is a sign of inflammation, the market is expected to rise as inflammation is also associated with OA.
The China market dominated the Asia Pacific C-reactive Protein Testing Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $274.4 million by 2030. The Japan market is estimated to witness a CAGR of 2.8% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 4.1% during (2023 - 2030).
Based on Application, the market is segmented into Cardiovascular Disease, Inflammatory Bowel Disease, Rheumatoid Arthritis, Diabetes, and Others. Based on Assay Type, the market is segmented into Immunoturbidimetric Assays, Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), and Others. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide C-reactive Protein Testing Market is Projected to reach USD 3.5 Billion by 2030, at a CAGR of 2.8%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Danaher Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Randox Laboratories Limited, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Horiba, Ltd., Merck KGaA, and Zoetis, Inc.
By Application
By Assay Type
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
